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Abstract
There are several signalling pathways involved in lung organogenesis including Notch, TGFβ /BMP,
Sonic hedgehog (Shh), FGF, EGF, and Wnt. Despite the widely acknowledged significance of Wnt
signalling in embryonic lung development, the role of different Wnt pathways in lung pathologies
has been slow to emerge.
In this review, we will present a synopsis of current Wnt research with particular attention paid to
the role of Wnt signals in lung development and in pulmonary diseases.
Overview of Wnt signalling
The Wnt family of 19 secreted glycoproteins control a vari-
ety of developmental processes including cell fate specifi-
cation, proliferation, polarity and migration.
Consequently, mis-regulation of Wnt signalling during
embryonic development cause developmental defects,
while defective Wnt signalling in adult tissue results in the
development of various diseases [1]. As Wnt-s have a
diverse role in regulating cell functions, Wnt signalling is
predictably complex. Wnt family members bind to cell
surface receptors called Frizzleds (Fz) and trigger intracel-
lular signalling cascades. The 10 Fz proteins are members
of the seven-loop transmembrane receptor family, and are
encoded by 9 genes. The assembly of an active receptor
complex also requires the presence of the co-receptor low
density lipoprotein related protein (LRP) 5/6.
There are at least three signalling pathways involved in the
signal transduction process: the canonical or β-catenin
dependent, and two non-canonical: the polar cell polarity
(PCP) or c-Jun N-terminal kinase (JNK)/ activating pro-
tein (AP) 1 dependent and the Ca2+ or protein kinase C
(PKC)/Calmodulin kinase (CaMK) II/ nuclear factor of
activated T cells (NFAT) dependent signalling pathways.
Wnt signalling is modulated by numerous regulatory mol-
ecules (for a review see [1,2]) and by frequent interactions
amongst the pathways themselves [3]. Wnt molecules
have been grouped as canonical (Wnt1, Wnt3, Wnt3a,
Wnt7a, Wnt7b, Wnt8) and non-canonical pathway activa-
tors (Wnt5a, Wnt4, Wnt11) [4]. The ability of the two
groups to trigger canonical or non-canonical signalling
cascades, however, is not absolute. Promiscuity of Wnt-s
and their receptors are a feature of this developmentally
and pathologically important glycoprotein family making
studies of Wnt signalling difficult.
Canonical Wnt-pathway
The canonical or β-catenin/Tcf dependent Wnt pathway
was discovered first, studied most and as a result reviewed
frequently [5,6]. Briefly, in the absence of Wnt signalling,
glycogen synthase kinase (GSK-3) is active and phospho-
rylates  β-catenin in the scaffolding protein complex of
adenomatous polyposis coli (APC) and axin [7,8]. The
phosporylated  β-catenin is targeted for ubiquitination
and 26S proteasome-mediated degradation, thereby
decreasing the cytosolic level of β-catenin [9,10] (Figure
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1). A Wnt-Fz-LRP6 complex is formed in the presence of
Wnt-s that leads to the phosphorylation of three domains
of Dishevelled (Dvl), which is a family of cytosolic signal
transducer molecules [11]. Activation of Dvl ultimately
leads to phosphorylation and consequently inhibition of
GSK-3. This process is summarised in Figure 2. Inhibition
of GSK3 results in stabilisation and consequently
cytosolic accumulation of β-catenin (Figure 2). The accu-
mulated β-catenin translocates to the nucleus, where it
forms an active transcription complex with members of
the T Cell Factor (LEF1, TCF1, TCF3, TCF4) transcription
factor family [12,13] and transcription initiator p300
[14]. Successful assembly of the transcription complex
leads to target gene activation. Target genes of the canon-
ical β-catenin pathway include matrix metalloproteinases
(MMP2, MMP3, MMP7, and MMP9) [15], cyclin D1
[16,17], Cox-2 [18], c-myc [19], c-jun [20], Fra-1 [20],
VEGFR [21], etc. (For a recent update see Nusse's Wnt
website: http://www.stanford.edu/~rnusse/wntwin
dow.html).
Non-canonical Wnt-pathways
The non-canonical Wnt pathways, the JNK/AP1 depend-
ent, PCP and the PKC/CAMKII/NFAT dependent Ca2+
pathway (just like the canonical Wnt pathway) become
activated following Wnt-Fz receptor binding [22,23]. The
non-canonical pathways differ from the β-catenin path-
way in their dependency on the type of G-proteins [24]
they require for activation. Further downstream, Dvl is
critical for signal transduction in both [25] but in contrast
to canonical Wnt signalling, phosphorylation of all three
domains of Dvl, is not a requirement [26]. Although the
Dvl family has long been accepted as cytosol based signal
transducers for the three Wnt-pathways, recent studies
have revealed the ability of Dvl to translocate into the
nucleus where it regulates intranuclear stability of β-cat-
enin [27,28]. How this new function of Dvl fits into the
more traditional role of the molecule awaits further inves-
tigation.
Nevertheless, downstream of the cytosolic Dvl, the two
non-canonical Wnt pathways can activate different signal-
ling cascades and trigger the transcription of different
gene-sets, although cross-pathway activation, signal inte-
gration, and consequently gene expression modification
via complex formation between NFAT and AP1 [29] can
also occur. The noncanonical pathways are summarised
in figure 3 and 4.
Ca2+ pathway
Following Dvl activation, the Ca-dependent Wnt signal-
ling pathway activates several downstream targets includ-
ing protein kinase C (PKC), Ca-Calmodulin kinase II
(CaMKII), and the Ca sensitive phosphatase, calcineurin
[30] before the activation of NFAT [31] occurs. NFAT is a
family of transcription factors that regulate activation-
induced transcription of many immunologically impor-
tant genes including interleukin(IL)-2, IL-4, IFN-γ, and
TNF-α [32]. Whether the genes outlined above are directly
regulated by Ca2+ dependent Wnt signals has yet to be
clarified. A prominent member of the non-canonical Wnt
pathway activators, Wnt 5a, has recently been connected
to pro-inflammatory cytokine (IL6, IL8, IL15) production
[33] implicating PKC and NFkB in the process [34],
although the role for both PKC and NFkB requires further
conformation.
JNK/AP1 dependent PCP pathway
In the PCP pathway, activation of Dvl leads to JNK, and in
turn to AP1 activation [35]. AP1 is not a single protein,
but a complex of smaller proteins, which can form homo-
and heterodimers. The main components of AP1 are cJun,
JunB, JunD, cFos, FosB, Fra1, Fra2, ATF2, and CREB. The
composition of the AP1 complex is a decisive factor in the
selection of genes targeted for activation. Therefore regu-
lation of the individual AP1 components is just as impor-
Inhibition of canonical Wnt signalling pathway in the absence  of Wnt signals Figure 1
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tant as the activation or inhibition of upstream members
of the pathway. cJun and Fra1, two prominent members
of the AP1 complex, have been identified as target genes
of the canonical Wnt signalling pathway [20], indicating
yet another potential for cross-regulation between the
canonical and the non-canonical Wnt pathways.
Several genes including cyclin D1 [36], MMP-3 [37], Bim
[38], GMCSF [39], which are also described as Wnt target
genes, are activated by AP1. Although identification of
Wnt-signal dependent AP1 target genes are awaiting fur-
ther investigation, recent studies have implicated both
cyclin D1 and MMP-3 as direct targets of JNK-dependent
Wnt signalling [40]. Intriguingly, activation of cyclin D1
gene transcription is triggered by a cFos and cJun het-
erodimer of the AP1 complex [41], in which cJun is a
canonical β-catenin pathway target gene. It certainly raises
the possibility, that regulation of cyclin D1 expression by
the PCP pathway is also influenced indirectly through
canonical Wnt signalling.
Regulation of Wnt signalling
The highly complex Wnt signalling pathways are central
to the regulation of a wide range of cell functions and
therefore tightly controlled. An armada of secreted extra-
cellular (DKK-s [42], sFRP-s [43,44], WIF [45], Cer [46])
and intracellular, both cytosolic (ICAT [47-49], Nkd [50])
and nuclear (Sox17 [51]), signal modulators make Wnt
signalling difficult to decipher. Further to individual
inhibitors, there is also cross-talk amongst different Wnt
signaling pathways. The non-canonical pathways, for
example, can also act as regulators of canonical Wnt sig-
nalling, often by influencing the phosphorylation and
therefore activation state of GSK (one of the main
enzymes of the canonical Wnt pathway) [52,53].
Furthermore, inhibitory Fz pathways have also been
described. Fz1 [54,55] inhibits Wnt signal transduction
via a G-protein dependent manner. The other inhibitory
Fz, Fz6, [56], inhibits Wnt dependent gene transcription
by activating a Ca dependent signalling cascade involving
TAK1 and Nemo-Like Kinase (NLK) [57,58], and ends
with the phosphorylation of TCF family members. The
resulting structural changes in TCF-s inhibit β-catenin TCF
binding and consequently activation of gene transcription
[57] (Figure 5).
Wnt signalling in the developing lung
Modulation of Wnt expression in embryonic and adult
mouse lung suggests that Wnt pathways are important for
cell fate decisions and differentiation of lung cell types.
The involvement of canonical Wnt signalling in lung
development has been proven by several ways. A TCF pro-
moter-LacZ based reporter system has shown, that canon-
ical Wnt signalling is active throughout lung development
in mouse embryos [59]. β-catenin, a central molecule of
canonical Wnt signalling, has been shown to localize in
the cytoplasm, and often also the nucleus of the undiffer-
entiated primordial epithelium (PE), differentiating alve-
olar epithelium (AE), and adjacent mesenchyme [60].
Using a conditional knockout system for β-catenin in
mice has also revealed that β-catenin dependent signal-
ling is central to the formation of the peripheral airways
of the lungs, responsible for conducting gas exchange, but
is dispensable for the formation of the proximal airways
[61]. Constitutive activation of the canonical Wnt path-
way using a β-catenin-Lef1 fusion protein, produced a
similar effect [59]. Although proximal airways developed,
the lung was reduced in size and lacked alveoli [59].
Recent studies have related particular Wnt production to
specific lung cell types. Wnt2 [62] for example has been
mapped predominantly to the mesenchyme, Wnt11 to
both epithelium and mesenchyme [63], while Wnt7b was
exclusively expressed in the lung epithelium [64]. Addi-
tional studies have revealed that Wnt7b promoter activity
Acitivation of canonical Wnt signalling pathway in the  absence of Wnt signals Figure 2
Activation of canonical Wnt signalling pathway in the 
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is regulated by a homeodomain transcription factor, TTF1,
which is essential to the differentiation of lung epithe-
lium, being especially important for the highly specialised
Type II alveolar epithelial cells [65]. Since the TTF1 null
mice have a lethal lung phenotype with increased epithe-
lial and mesenchymal proliferation, which at the neonatal
stage contains abundant mesenchyme and no functional
alveoli [65], it is likely that the lack of functional alveoli is
a result of dysregulated Wnt7b signalling [64].
Apart from β-catenin and Wnt-s, mRNA of Fz-1, -2 and -7
and several intracellular signalling molecules including
Tcf-1, -3, -4, Lef1, and secreted Fz related proteins (sFrp-1,
-2 and -4) have been found to be expressed in the devel-
oping lung [60] in specific, spatio-temporal patterns [60].
Wnt signalling has also been reported to be important in
the regulation of spatial and distal branching of the lung
[61].
While the importance of canonical Wnt signalling in lung
development is well established, the role of non-canoni-
cal Wnt signalling is less clear. Wnt5a knock-out studies
have shown, however, that non-canonical Wnt signalling
is also important. In Wnt5a-/- animals the lung is mor-
phologically smaller than in the wild type [66] and has
thickened mesenchyme. Furthermore, alveolar develop-
ment is delayed, although not prevented [66]. Lungs of
Wnt5a knock-out animals also have increased expression
of FGF10 and Shh [66,67] suggesting that the morpholog-
ical changes might be related to dysregulation of other sig-
nalling pathways modulated by Wnt signalling (see below
for further details).
Wnt-s in adult lung
Primary lung tissue and cell lines, derived from adult lung
tissue, express a wide range of Wnt-s including Wnt-3, -4,
-5a, -7a, -7b, -10b, and -11 [68], as well as Fz-3, -6 and -7
[68], Dvl [69], and Dkk [70]. Since, generally, Wnt signal-
ling retains cells in a low differentiation state, the role of
Wnt signalling in adult tissue may not be immediately
clear. If we assume that the maintenance of adult organs
is stem cell dependent and that stem cells rely on β-cat-
enin and Tcf/Lef signalling to be maintained in the
required low differentiation level, the role of Wnt signals
in adult tissue becomes understandable. Stem cell niches
in proximal and distal airways exist [71,72], similarly to
intestine, hair follicle and dermis, and would need Wnt
signalling to be able to fulfill their role in maintenance of
adult lung structure.
Wnt in lung carcinoma
While lung cancer is one of the leading causes of cancer
deaths worldwide [73,74] data regarding the role of Wnt
pathways in human lung cancer is still limited. The most
studied pathway mutations in cancer are the inherited and
sporadic mutations in the tumour suppressor adenoma-
tous polyposis coli (APC) and β-catenin. Since APC is part
of the degradation scaffold for β-catenin, mutations of
APC can result in reduced degradation and increased
nuclear accumulation of β-catenin leading to activation of
target genes such as oncogenes cyclin D1 and c-myc [75].
Degradation resistant β-catenin has similar effect on target
gene activation [59]. Although increased levels of β-cat-
enin have been reported in different types of lung cancers
[76,77], mutations of APC [78] and β-catenin [79,80] are
rare in lung cancers. However, proof of dysregulation of
specific Wnt molecules leading to oncogenic signalling
has emerged. While frequent loss of Wnt7a mRNA was
demonstrated in some studies in lung cancer cell lines and
primary tumours [81], elevated levels of Wnt1 [82] and
Wnt2 [83] have been reported in non small cell lung can-
cer. Decreased levels of Wnt7a indicates that Wnt7a may
function as a tumour suppressor in lung cancer. In sup-
port this concept, non-small-cell lung cancer cells trans-
formed with Wnt7a showed inhibition of anchorage
independent growth [68]. Although member of the
canonical group, Wnt7a inhibits proliferation and
induces differentiation via the JNK/AP1 dependent PCP
signalling pathway [68]. The role of non-canonical Wnt
signalling in the development of lung cancer remains con-
Activation of non-canonical Wnt signalling Figure 3
Activation of non-canonical Wnt signalling.
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troversial despite recent findings. Although the non-
canonical pathway activator Wnt5a is an important regu-
lator of lung development, and generally is an inhibitor of
canonical Wnt signalling, elevated levels of Wnt5a in lung
metastases of human sarcoma [84] has been reported and
thus questions the role of non-canonical Wnt signalling as
a general inhibitor of lung cancer. In metastatic stage of
any tumours including human lung carcinomas, epithe-
lial-mesenchymal transformation (EMT) is typical [85]
and generally linked to increased β-catenin dependent sig-
nalling [86]. As β-catenin mutations in lung cancers are
relatively rare [79,80,87], another possible mechanism
might be at place which regulates EMT and consequently
tumour metastasis in the lung. Certainly, non-canonical
Wnt5a the very molecule which has recently been
reported to regulate fibroblast growth factor (FGF) 10 and
sonic hedgehog (Shh) expression [67] has been found ele-
vated in lung metastases [84]. Both FGF-s and the hedge-
hog family are well-known modulators of epithelial-
mesenchymal interactions [88] and epithelial-mesenchy-
mal transformations (EMT) [89-91]. Dysregulation of FGF
and Shh signalling certainly raises the possibility that
Wnt5a and perhaps non-canonical Wnt signalling in gen-
eral, is indirect regulator of lung tumour metastasis.
Lung developmental studies have also provided support
for the involvement of canonical Wnt signalling in lung
cancer. Constitutive activation of the canonical pathway
in the developing lung resulted in a non-differentiated
lung phenotype resembling cancer [59]. Target genes of
the canonical and PCP Wnt pathways include matrix met-
alloproteinases, which are essential for tissue remodelling
and are elevated in invasive cancer [92,93], thus providing
additional evidence for the involvement of Wnt signalling
in lung cancer.
Overexpression of Dvl, a positive regulator of Wnt signal-
ling pathways has been reported in 75% of non-small-
cell-lung-cancer samples compared with autologous
matched normal tissue [94]. Downregulation of Wnt
pathway antagonists like Dkk3 [70], WIF [95,96] and
sFRP [97] have also been reported in various types of lung
cancers providing further evidence of the role of this com-
plex pathway.
Wnt in lung inflammation
To date there is no direct evidence for the involvement of
Wnt signalling in inflammation of the central airways.
However, based on the general features of inflammatory
diseases and evidence for Wnt regulated signalling in
inflammation in the joint [34], we have addressed the
potential involvement of Wnt signalling in inflammatory
diseases of the lung.
Increased levels of pro-inflammatory and inflammatory
cytokines such as IL1, IL6, IL8, and IL15, monocyte chem-
otactic protein-1 (MCP-1), TNFα and intercellular adhe-
sion molecule-1 (ICAM-1) are general features of
inflammation. The elevated expression of ICAM in the
epithelium is important in leukocyte recruitment, adhe-
sion and retention [98], while IL8 secreted by the bron-
chial epithelium [99], is thought to be central to the
attraction of neutrophils. Neutrophils together with mac-
rophages contribute to the pathogenesis of inflammatory
tissue injury by reactive oxygen metabolites and protein-
ase release. Increased levels of tissue matrix metalloprotei-
nases (MMP-s) are a feature of inflammatory conditions
and may contribute to the overall evolution of the inflam-
mation-induced tissue destruction. Several pulmonary
cells including resident alveolar macrophages, neu-
trophils, parenchymal cells (including interstitial fibrob-
lasts), type II epithelial cells and vascular endothelial cells
are capable of elaborating MMPs [100], and numerous
MMP-s, including MMP3 and MMP9, have been consid-
ered to have important pro-inflammatory roles in acute
lung inflammation [101]. Activation of MMP gene tran-
scription has been attributed to both pro-inflammatory
cytokines [102,103] and canonical Wnt signalling [15],
but it is still not clear whether they act in competition or
in close connection to regulate the transcription of MMP
Activation of non-canonical Wnt signalling Figure 4
Activation of non-canonical Wnt signalling.
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genes. Certainly, the canonical pathway activator Wnt-1
has been linked to stimulation of pro-MMP3 transcription
[104], which is implicated in lung inflammation [105].
Understanding of signalling pathway interaction is thus of
importance in the study of pathogenic processes and
hence disease modulation.
Studies of rheumatoid arthritis have accumulated evi-
dence that Wnt5a-Fz5 mediated signalling can contribute
significantly to the production of pro-inflammatory
cytokines (IL6, IL8, IL15) [33] and that overexpression of
Wnt5a leads to increased pro-inflammatory cytokine lev-
els. Furthermore, dominant negative and antisense Wnt5a
and anti-Fz-5 antibody block Wnt5-Fz5 signalling leading
to decreased cytokine production [33].
Additionally, the inflammatory cytokine inducing Wnt5a
has also been implicated in the down-regulation of Shh
levels in the lung [67]. Elevated Shh signalling is well
established in the regulation of inflammatory and fibrotic
processes of the gut and lung [91]. This suggests a role for
Wnt5a but further investigation would be necessary to
clarify this in the central airways- in pulmonary inflam-
mation.
Wnt in lung fibrosis
Lung diseases resulting in tissue damage activate a defence
mechanism to repair the lesions. Tissue damage can result
from several acute and chronic stimuli including inflam-
mation caused by infections, autoimmune reactions
(asthma, allergic alveolitis), and drugs and toxins (bleo-
mycin, asbestos) or mechanical injury (surgery, and irra-
diation). Any tissue repair involves coordinated cellular
infiltration together with extracellular matrix deposition
and where appropriate, re-epitheliasation. In the first
regenerative step, injured cells are replaced by cells of the
same type, then normal parenchyma is replaced by con-
nective tissue leading to fibrosis. Usually both steps are
required for healing, however, when the fibrotic step
becomes uncontrolled and pathogenic, the process can
lead to organ failure and death. The interstitial lung dis-
ease (ILD) includes a wide range of disorders in which
pulmonary inflammation and fibrosis are the final com-
mon pathway.
Generally, any activated state of tissue repair requires the
stimulation of signalling pathways involved in prolifera-
tion, cell migration and differentiation. It is therefore
understandable that the fibrotic process is influenced by a
combination of growth factors (such as TGFβ, FGF), and
cell adhesion molecules (such as integrins). Modulation
of growth factor expression, loss of E-cadherin and activa-
tion of β-catenin dependent gene transcription leads to
epithelial-mesenchymal transition (EMT) which is also an
important feature of the fibrotic process. Direct involve-
ment of canonical Wnt signalling in EMT has been con-
firmed in studies using Wnt1 and Lef-1 overexpression
[106]. Furthermore, during cellular migration, which is an
important factor in tissue repair, proteolytic degradation
of the extracellular matrix is necessary to enable fibrob-
lasts to migrate through the extracellular matrix to the site
of the lesion. Proteolytic degradation of the extracellular
matrix requires plasminogen and matrix metalloprotein-
ases [107,108]. Gene transcription of MMP-s is regulated
by Wnt signalling of both canonical and non-canonical
pathways. Metalloproteinase matrilysin (MMP7), a target
gene of the canonical Wnt signalling pathway [109], has
recently been identified as a key regulator of pulmonary
fibrosis [110,111]. In many cases of idiopathic pulmonary
fibrosis, the levels of nuclear β-catenin are elevated [112],
as are the levels of β-catenin target genes, cyclin D1 and
MMP-s [112].
As Wnt-s have also been implicated in the modulation of
proliferation and differentiation of many lung cells
[59,60,66], the role of Wnt signalling in regulating cell
proliferation and differentiation during idiopathic pul-
monary fibrosis, is likely to be central rather than a conse-
quence of the disease.
Inhibition of Wnt signalling by a Fz-dependent pathway Figure 5
Inhibition of Wnt signalling by a Fz-dependent pathway.
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In summary, Wnt signalling may also be central to all
causes of pulmonary fibrosis and requires further evalua-
tion.
Interaction of Wnt pathways with FGF, TGFβ /
BMP/Smad pathways
Although detailed discussion of interactions of Wnt with
other signalling pathways is not the aim of the present
review, it is still important to highlight some regulatory
interactions, which might also play a role in development
and control of pulmonary diseases. Certainly, the non-
canonical pathway activator Wnt5a has been implicated
in the regulation of several signalling pathways. In Wn5a-
/- knockout animals there is increased FGF10 and BMP4
expression [66] suggesting a key role of Wnt5a in the reg-
ulation of both factors. Since FGF10 stimulates prolifera-
tion and branching in the developing lung and also
induces delayed distal epithelial BMP4 expression, which
eventually inhibits lung bud outgrowth [113], Wnt5a
appears to be a key regulator of cellular proliferation in
the lung.
The effect of Wnt-s as signal modulators of other signal-
ling pathways has also been demonstrated. For example,
the canonical Wnt pathway inhibitor, ICAT [47], regulates
the expression of the BMP pathway inhibitor, BAMBI
(BMP and activin membrane-bound inhibitor) [114].
Since ICAT functions by blocking binding sites of TCF-s
and p300 on the armadillo domains of β-catenin [47] and
therefore inhibiting β-catenin dependent gene transcrip-
tion, this suggests that BAMBI is not only directly control-
led by BMP4 [115] but also by canonical Wnt signalling.
Moreover, both the TGFβ and BMP pathways require
Smad-s (reviewed in [116]) for signal transduction but
Smad-dependent gene transcription can also be modu-
lated by β-catenin [117,118], binding to Smad-nuclear
complexes. A role for the Smad-system activator TGFβ 1 in
pulmonary fibrogenesis has recently been confirmed
[119]. It was shown that TGFβ 1 has a direct role in regu-
lating EMT by promoting alveolar epithelial cell transition
to form mesenchymal cells with a myofibroblast-like phe-
notype. As both TGFβ and β-catenin signalling induces
EMT, a Wnt/TGF signal interaction became evident once
again emphasising the need for further studies to define
details of signal transduction and pathway coordination
to fully understand the underlying processes of EMT.
Since FGF, Shh, TGFβ, and BMP signalling pathways are
all important in tissue repair, fibrosis and cancer invasion,
it appears, that Wnt signalling can modulate disease pro-
gression both directly and indirectly by activating gene
transcription and modulating and cross-regulating signal-
ling pathways.
Summary
The involvement of Wnt signalling in lung development,
maintenance, cancer, and repair (including idiopathic
pulmonary fibrosis) is supported by evidence, while
based on indirect evidence a role for Wnt signalling in
inflammatory lung diseases can also be postulated. Cer-
tainly, better understanding of Wnt signalling in the lung
is likely to be important and provide information central
to new treatment approaches for a wide variety of lung
diseases.
References
1. Logan C, Nusse R: The Wnt signaling pathway in development
and disease.  Annu Rev Cell Dev Biol 2004, 20:781-810.
2. Miller JRHAMBJDMRT: Mechanism and function of signal trans-
duction by the Wnt/b-catenin and Wnt/Ca2+ pathways.
Oncogene 1999, 18:7860-7872.
3. Kuhl M, Geis K, Sheldahl LC, Pukrop T, Moon RT, Wedlich D:
Antagonistic regulation of convergent extension move-
ments in Xenopus by Wnt/beta-catenin and Wnt/Ca2+ sig-
nalling.  Mech Dev 2001, 106:61-76.
4. Torres MA, Yang-Snyder JA, Purcell SM, DeMarais AA, McGrew LL,
Moon RT: Activities of the Wnt-1 class of secreted signaling
factors are antagonized by the Wnt-5A class and by a domi-
nant negative cadherin in early Xenopus development.  J Cell
Biol 1996, 133:1123-1137.
5. Reya T, Clevers H: Wnt signalling in stem cells and cancer.
Nature 2005, 434:843-850.
6. Moon RT, Kohn AD, De Ferrari GV, Kaykas A: WNT and beta-cat-
enin signalling: diseases and therapies.  Nat Rev Genet 2004,
5:691-701.
7. Ikeda SKSYHMHKSKA: Axin, a negative regulator of the Wnt
signaling pathway, forms a complex with GSK3b and b-cat-
enin and promotes GSK-3b-dependent phosphorylation of b-
catenin.  The EMBO J 1998, 17:1371-1384.
8. Yamamoto HKSKMISTSKA: Phosphorylation of axin, a Wnt sig-
nal negative regulator, by glycogen synthase kinase-3beta
regulates its stability.  EMBO J 1999, 274:10681-10684.
9. Aberle HBASJKAKR: b-Catenin is a target for the ubiquitin-
proteosome pathway.  EMBO J 1997, 16:3797-3804.
10. Akiyama T: Wnt/b-catenin signaling.  Cytokine&Growth Factor Rev
2000, 11:273-282.
11. Noordermeer JKJPNNR: Dishevelled and armadillo act in the
wingless signalling pathway in Drosophila.  Nature 1994,
367:80-83.
12. van Noort M, Clevers H: TCF transcription factors, mediators
of Wnt-signaling in development and cancer.  Dev Biol 2002,
244:1-8.
13. Young CSKMHSKJ: Wnt-1 induces growth, cytosolic beta-cat-
enin, and Tcf/Lef transcriptional activation in Rat-1 fibrob-
lasts.  Mol Cell Biol 1998, 18:2474-2485.
14. Labalette C, Renard CA, Neuveut C, Buendia MA, Wei Y: Interac-
tion and functional cooperation between the LIM protein
FHL2, CBP/p300, and beta-catenin.  Mol Cell Biol 2004,
24:10689-10702.
15. Tamamura Y, Otani T, Kanatani N, Koyama E, Kitagaki J, Komori T,
Y a m a d a  Y ,  C o s t a n t i n i  F ,  W a k i s a k a  S ,  P a c i f i c i  M ,  I w a m o t o  M ,
Enomoto-Iwamoto M: Developmental regulation of Wnt/beta-
catenin signals is required for growth plate assembly, carti-
lage integrity, and endochondral ossification.  J Biol Chem 2005,
280:19185-19195.
16. Shtutman M, Zhurinsky J, Simcha I, Albanese C, D'Amico M, Pestell R,
Ben-Ze'ev A: The cyclin D1 gene is a target of the beta-cat-
enin/LEF-1 pathaway.  Proc Natl Acad Sci USA 1999, 96:5522-5527.
17. Tetsu O, McCormick F: Beta-catenin regulates expression of
cyclin D1 in colon carcinoma cells.  Nature 1999, 398:422-426.
18. Longo KA, Kennell JA, Ochocinska MJ, Ross SE, Wright WS, MacDou-
gald OA: Wnt signaling protects 3T3-L1 preadipocytes from
apoptosis through induction of insulin-like growth factors.  J
Biol Chem 2002, 277:38239-38244.Respiratory Research 2006, 7:15 http://respiratory-research.com/content/7/1/15
Page 8 of 10
(page number not for citation purposes)
19. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT,
Morin PJ, Vogelstein B, Kinzler KW: Identification of c-MYC as a
target of the APC pathway.  Science 1998, 281:1509-1512.
20. Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ilyas M, Bodmer
WF, Moyer MP, Riecken EO, Buhr HJ, C H: Target genes of beta-
catenin-T cell-factor/lymphoid-enhancer-factor signaling in
human colorectal carcinomas.  Proc Natl Acad Sci USA 1999,
96:1603-1608.
21. Zhang X, Gaspard JP, Chung DC: Regulation of vascular endothe-
lial growth factor by the Wnt and K-ras pathways in colonic
neoplasia.  Cancer Res 2001, 61:6050-6054.
22. Kuhl M, Sheldahl LC, Park M, Miller JR, Moon RT: The Wnt/Ca2+
pathway  a new vertebrate Wnt signaling pathway takes
shape.  TIG 2000, 16:279-283.
23. Pandur P, Maurus D, Kuhl M: Increasingly complex: new players
enter the Wnt signaling network.  Bioassays 2002, 24:.
24. Malbon CC, Wang H, Moon RT: Wnt signaling and heterot-
rimeric G-proteins: strange bedfellows or a classic romance?
Biochem Biophys Res Commun 2001, 287:589-593.
25. Sheldahl LC, Slusarski DC, Pandur P, Miller JR, Kuhl M, Moon RT:
Dishevelled activates Ca2+ flux, PKC, and CamKII in verte-
brate embryos.  J Cell Biol 2003, 161:767-777.
26. Yan D, Wallingford JB, Sun TQ, Nelson AM, Sakanaka C, Reinhard C,
Harland RM, Fantl WJ, Williams LT: Cell autonomous regulation
of multiple Dishevelled-dependent pathways by mammalian
Nkd.  Proc Natl Acad Sci USA 2001, 98:3802-3807.
27. Rothbacher U, Laurent MN, Deardorff MA, Klein PS, Cho KWY, Fra-
ser SE: Dishevelled phosphorylation, subcellular localization
and multimerization regulate its role in early embryogene-
sis.  The EMBO J 2000, 19:1010-1022.
28. Itoh K, Brott BK, Bae GU, Ratcliffe MJ, Sokol SY: Nuclear localiza-
tion is required for Dishevelled function in Wnt/b-catenin
signaling.  J Biol 2005, 4:3:.
29. Macian F, Garcia-Rodriguez C, Rao A: Gene expression elicited by
NFAT in the presence or absence of cooperative recruit-
ment of Fos and Jun.  EMBO J 2000, 19:4783-4795.
30. Rao A, Luo C, Hogan PG: Transcription factors of the NFAT
family: regulation and function.  Annu Rev Immunol 1997,
15:707-747.
31. Saneyoshi T, Kume S, Amasaki Y, Mikoshiba K: The Wnt/calcium
pathway activates NF-AT and promotes ventral cell fate in
Xenopus embryos.  Nature 2002, 417:295-299.
32. Oum JH, Han J, Myung H, Hleb M, Sharma S, Park J: Molecular
mechanism of NFAT family proteins for differential regula-
tion of the IL-2 and TNF-alpha promoters.  Mol Cells 2002,
13:77-84.
33. Sen M, Lauterbach K, El-Gabalawy H, Firestein GS, Corr M, Carson
DA:  Expression and function of wingless and frizzled
homologs in rheumatoid arthritis.  Proc Natl Acad Sci USA 2000,
97:2791-2796.
34. Sen M: Wnt signalling in rheumatoid arthritis.  Rheumatology
2005, 44:708-713.
35. Kishida S, Yamamoto H, Kikuchi A: Wnt-3a and Dvl induce neur-
ite retraction by activating Rho-associated kinase.  Mol Cell Biol
2004, 24:4487-44501.
36. Schwabe RF, Bradham CA, Uehara T, Hatano E, Bennett BL, Schoon-
hoven R, Brenner DA: c-Jun-N-terminal kinase drives cyclin D1
expression and proliferation during liver regeneration.  Hepa-
tology 2003, 37:824-832.
37. Buttice G, Duterque-Coquillaud M, Basuyaux JP, Carrere S, Kurkinen
M, Stehelin D: Erg, an Ets-family member, differentially regu-
lates human collagenase1 (MMP1) and stromelysin1 (MMP3)
gene expression by physically interacting with the Fos/Jun
complex.  Oncogene 1996, 13:2297-2306.
38. Putcha GV, Le S, Frank S, Besirli CG, Clark K, Chu B, Alix S, Youle RJ,
LaMarche A, Maroney AC, Johnson EMJ: JNK-mediated BIM phos-
phorylation potentiates BAX-dependent apoptosis.  Neuron
2003, 38:899-914.
39. Ye J, Zhang X, Dong Z: Characterization of the human granu-
locyte-macrophage colony-stimulating factor gene pro-
moter: an AP1 complex and an Sp1-related complex
transactivate the promoter activity that is suppressed by a
YY1 complex.  Mol Cell Biol 1996, 16:157-167.
40. Nateri AS, Spencer-Dene B, Behrens A: Interaction of phosphor-
ylated c-Jun with TCF4 regulates intestinal cancer develop-
ment.  Nature 2005, July 10, Epub:.
41. Mechta F, Lallemand D, Pfarr CM, Yaniv M: Transformation by ras
modifies AP1 composition and activity.  Oncogene 1997,
14:837-847.
42. Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C:
Dickkopf-1 is a member of a new family of secreted proteins
and functions in head induction.  Nature 1998, 391:357-362.
43. Yoshino K, Rubin JS, Higinbotham KG, Uren A, Anest V, Plisov SY,
Perantoni AO: Secreted Frizzled-related proteins can regulate
metanephric development.  Mech Dev 2001, 102:45-55.
44. Dennis SAMSWAPAPJ: A secreted Frizzled related protein,
FrzA, selectively associates with Wnt-1 protein and regu-
lates Wnt-1 signaling.  J Cell Sci 1999, 112:3815-3820.
45. Hsieh JC, Kodjabachian L, Rebbert ML, Rattner A, Smallwood PM,
Samos CH, Nusse R, Dawid IB, Nathans J: A new secreted protein
that binds to Wnt proteins and inhibits their activities.
Nature 1999, 398:431-436.
46. Glinka A, Wu W, Onichtchouk D, Blumenstock C, Niehrs C: Head
induction by simultaneous repression of Bmp and Wnt sig-
nalling in Xenopus.  Nature 1997, 391:.
47. Tago K, Nakamurea T, Nishita M, Hyodo J, Nagai S, Murata Y, Adachi
S, Ohwada S, Morishaita Y, Shibuya H, Akiyama T: Inhibition of
Wnt signaling by ICAT, a novel b-catenin-interacting pro-
tein.  Genes&Development 2000, 14:1741-1749.
48. Gottardi CJ, Gumbiner BM: Role for ICAT in b-catenin-depend-
ent nuclear signaling and cadherin functions.  Am J Physiol Cell
Physiol 2003, 286:C747-C756.
49. Daniels DL, Weis WI: ICAT inhibits beta-catenin binding to
Tcf/Lef-family transcription factors and the general coactiva-
tor p300 using independent structural modules.  Mol Cell 2002,
10:573-584.
50. Wharton Jr. KAZGRRSMP: Vertebrate proteins related to Dro-
sophila naked cuticle bind dishevelled and antagonize Wnt
signaling.  Developmental Biology 2001, 234:93-106.
51. Zorn AM, Barish GD, Williams BO, Lavender P, Klymkowsky MW,
Varmus HE: Regulation of Wnt signaling by Sox proteins:
XSox17 alpha/beta and XSox3 physically interact with beta-
catenin.  Mol Cell 1999, 4:487-498.
52. Oriente F, Formisano P, Miele C, Fiory F, Maitan MA, Vigliotta G,
Trencia A, Santopietro S, Caruso M, Van Obberghen E, Beguinot F:
Insulin receptor substrate-2 phosphorylation is necessary for
protein kinase C zeta activation by insulin in L6hIR cells.  J Biol
Chem 2001, 276:37109-37119.
53. Ossipova O, Bardeesy N, DePinho RA, Green JB: LKB1 (XEEK1)
regulates Wnt signalling in vertebrate development.  Nat Cell
Biol 2003, 5:889-894.
54. Roman-Roman S, Shi DL, Stiot V, Hay E, Vayssiere B, Garcia T, Baron
R, Rawadi G: Murine Frizzled-1 behaves as an antagonist of the
canonical Wnt/beta-catenin signaling.  J Biol Chem 2004,
279:5725-5733.
55. Zilberberg A, Yaniv A, Gazit A: The low density lipoprotein
receptor-1, LRP1, iteracts with the human Frizzled-1 (HFz1)
and down-regulates the canonical Wnt signaling pathway.  J
Biol Chem 2004, 279:17535-17542.
56. Golan T, Yaniv A, Bafico A, Liu G, Gazit A: The human frizzled 6
(HFz6) acts as a negative regulator of the canonical Wnt b-
catenin signaling cascade.  J Biol Chem 2004, 279:14879-14888.
57. Ishitani T, Kishida S, Hyodo-Miura J, Ueno N, Yasuda J, Waterman M,
Shibuya H, Moon RT, Ninomiya-Tsuji J, Matsumoto K: The TAK1-
NLK Mitogen-activated protein kinase cascade functions in
the Wnt-5a/Ca2+ pathway to antagonize Wnt/b-catenin sig-
naling.  Mol Cell Biol 2003, 23:131-139.
58. Smit L, Baas A, Kuipers J, Korswagen H, van de Wetering M, Clevers
H: Wnt activates the Tak1/Nemo-like kinase pathway.  J Biol
Chem 2004, 279:17232-17240.
59. Okubo T, Hogan BLM: Hyperactive Wnt signaling changes the
developmental potential of embryonic lung endoderm.  J Biol
2004, 3:.
60. Tebar M, Destree O, de Vree WJ, Ten Have-Opbroek AA: Expres-
sion of Tcf/Lef and sFrp and localization of beta-catenin in
the developing mouse lung.  Mech Dev 2001, 109:437-440.
61. Mucenski ML, Wert SE, Nation JM, Loudy DE, Huelsken J, Birchmeier
W, Morrisey EE, Whitsett JA: b-catenin is required for specifica-
tion of proximal/distal cell fate during lung morphogenesis.  J
Biol Chem 2003, 278:40231-40238.Respiratory Research 2006, 7:15 http://respiratory-research.com/content/7/1/15
Page 9 of 10
(page number not for citation purposes)
62. Monkley SJ, Delaney SJ, Pennisi DJ, Christiansen JH, Wainwright BJ:
Targeted disruption of the Wnt2 gene results in placenta-
tion defects.  Development 1996, 122:3343-3353.
63. Lako M, Strachan T, Bullen P, Wilson DI, Robson SC, Lindsay S: Iso-
lation, characterisation and embryonic expression of
WNT11, a gene which maps to 11q13.5 and has possible
roles in the development of skeleton, kidney and lung.  Gene
1998, 219:101-110.
64. Weidenfeld J, Shu W, Zhang I, Millar SE, Morrisey EE: The Wnt7b
promoter is regulated by TTF-1, GATA6, and Foxa2 in lung
epithelium.  J Biol Chem 2002, 277:21061-21070.
65. Minoo P, Hamdan H, Bu D, Warburton D, Stepanik P, deLemos R:
TTF-1 regulates lung epithelial morphogenesis.  Dev Biol 1995,
172:694-698.
66. Li C, Xiao J, Hormi K, Borok Z, Minoo P: Wnt5a participates in
distal lung morphogenesis.  Dev Biol 2002, 248:68-81.
67. Li C, Hu L, Xiao J, Chen H, Li JT, Bellusci S, Delanghe S, Minoo P:
Wnt5a regulates Shh and Fgf10 signaling during lung devel-
opment.  Dev Biol 2005, 287:86-97.
68. Winn RA, Marek L, Han SY, Rodriguez K, Rodriguez N, Hammond M,
Van Scoyk M, Acosta H, Mirus J, Barry N, Bren-Mattison Y, Van Raay
TJ, Nemenoff RA, Heasley LE: Restoration of Wnt-7a expression
reverses non-small cell lung cancer cellular transformation
through frizzled-9-mediated growth inhibition and promo-
tion of cell differentiation.  J Biol Chem 2005, 280:19625-19634.
69. Pizzuti A, Amati F, Calabrese G, Mari A, Colosimo A, Silani V, Gia-
rdino L, Ratti A, Penso D, Calza L, Palka G, Scarlato G, Novelli G, B
D:  cDNA characterization and chromosomal mapping of
two human homologues of the Drosophila dishevelled polar-
ity gene.  Hum Mol Genet 1996, 5:953-958.
70. Nozaki I, Tsuji T, Iijima O, Ohmura Y, Andou A, Miyazaki M, Shimizu
N, Namba M: Reduced expression of REIC/Dkk-3 gene in non-
small cell lung cancer.  Int J Oncol 2001, 19:117-121.
71. Borthwick DW, Shahbazian M, Krantz QT, Dorin JR, Randell SH: Evi-
dence for stem-cell niches in the tracheal epithelium.  Am J
Respir Cell Mol Biol 2001, 24:662-670.
72. Bi K, Tanaka Y, Coudronniere N, Sugie K, Hong S, van Stipdonk MJ,
A A: Antigen-induced translocation of PKC-theta to mem-
brane rafts is required for T cell activation.  Nat Immunol 2001,
2:556-563.
73. Minna JD, Roth JA, Gazdar AF: Focus on lung cancer.  Cancer Cell
2002, 1:49-52.
74. Jemal A, Clegg LX, Ward E, Ries LA, Wu X, Jamison PM, Wingo PA,
Howe HL, Anderson RN, Edwards BK: Annual report to the
nation on the status of cancer, 1975-2001, with a special fea-
ture regarding survival.  Cancer 2004, 101:3-27.
75. Venesio T, Balsamo A, Scordamaglia A, Bertolaso M, Arrigoni A, Spru-
jevnik T, Rossini FP, Risio M: Germline APC mutation on the
beta-catenin binding site is associated with a decreased
apoptotic level in colorectal adenomas.  Mod Pathol 2003,
16:57-65.
76. Kotsinas A, Evangelou K, Zacharatos P, Kittas C, Gorgoulis VG: Pro-
liferation, but not apoptosis, is associated with distinct beta-
catenin expression patterns in non-small-cell lung carcino-
mas: relationship with adenomatous polyposis coli and G(1)-
to S-phase cell-cycle regulators.  Am J Pathol 2002,
161:1619-1634.
77. Sekine S, Shibata T, Matsuno Y, Maeshima A, Ishii G, Sakamoto M,
Hirohashi S: Beta-catenin mutations in pulmonary blastomas:
association with morule formation.  J Pathol 2003, 200:214-221.
78. Ohgaki H, Kros JM, Okamoto Y, Gaspert A, Huang H, Kurrer MO:
APC mutations are infrequent but present in human lung
cancer.  Cancer Lett 2004, 207:197-203.
79. Sunaga N, Kohno T, Kolligs FT, Fearon ER, Saito R, Yokota J: Consti-
tutive activation of the Wnt signaling pathway by CTNNB1
(beta-catenin) mutations in a subset of human lung adeno-
carcinoma.  Genes Chromosomes Cancer 2001, 30:316-321.
80. Ueda M, Gemmill RM, West J, Winn R, Sugita M, Tanaka N, Ueki M,
Drabkin HA: Mutations of the beta- and gamma-catenin genes
are uncommon in human lung, breast, kidney, cervical and
ovarian carcinomas.  Br J Cancer 2001, 85:64-68.
81. Calvo R, West J, Franklin W, Erickson P, Bemis L, Li E, Helfrich B,
Bunn P, Roche J, Brambilla E, Rosell R, Gemmill RM, Drabkin HA:
Altered HOX and WNT7A expression in human lung can-
cer.  Proc Natl Acad Sci USA 2000, 97:12776-12781.
82. He B, You L, Uematsu K, Xu Z, Lee AY, Matsangou M, McCormick F,
Jablons DM: A monoclonal antibody against Wnt-1 induces
apoptosis in human cancer cells.  Neoplasia 2004, 6:7-14.
83. You L, He B, Xu Z, Uematsu K, Mazieres J, Mikami I, Reguart N,
Moody TW, Kitajewski J, McCormick F, Jablons DM: Inhibition of
Wnt-2-mediated signaling induces programmed cell death in
non-small-cell lung cancer cell.  Oncogene 2004, 23:6170-6174.
84. Nakano T, Tani M, Ishibashi Y, Kimura K, Park YB, Imaizumi N, Tsuda
H, Aoyagi K, Sasaki H, Ohwada S, Yokota J: Biological properties
and gene expression associated with metastatic potential of
human osteosarcoma.  Clin Exp Metastasis 2003, 20:665-674.
85. Taki M, Kamata N, Yokoyama K, Fujimoto R, Tsutsumi S, Nagayama
M: Down-regulation of Wnt-4 and up-regulation of Wnt-5a
expression by epithelial-mesenchymal transition in human
squamous carcinoma cells.  Cancer Sci 2003, 94:593-597.
86. Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung
A, Kirchner T: Invasion and metastasis in colorectal cancer:
epithelial-mesenchymal transition, mesenchymal-epithelial
transition, stem cells and beta-catenin.  Cells Tissues Organs
2005, 179:56-65.
87. Blanco D, Vicent S, Elizegi E, Pino I, Fraga MF, Esteller M, Saffiotti U,
Lecanda F, Montuenga LM: Altered expression of adhesion mol-
ecules and epithelial-mesenchymal transition in silica-
induced rat lung carcinogenesis.  Lab Invest 2004, 84:999-1012.
88. Cardoso WV: Lung morphogenesis revisited: old facts, cur-
rent ideas.  DevDyn 2000, 219:121-130.
89. Arbeit JM, Olson DC, Hanahan D: Upregulation of fibroblast
growth factors and their receptors during multi-stage epi-
dermal carcinogenesis in K14-HPV16 transgenic mice.  Onco-
gene 1996, 13:1847-1857.
90. Shimizu Y, Yamamichi N, Saitoh K, Watanabe A, Ito T, Yamamichi-
Nishina M, Mizutani M, Yahagi N, Suzuki T, Sasakawa C, Yasugi S, Ich-
inose M, Iba H: Kinetics of v-src-induced epithelial-mesenchy-
mal transition in developing glandular stomach.  Oncogene
2003, 22:884-893.
91. Nielsen CM, Williams J, van den Brink GR, Lauwers GY, Roberts DJ:
Hh pathway expression in human gut tissues and in inflam-
matory gut diseases.  Lab Invest 2004, 84:1631-1642.
92. Kossakowska AE, Huchcroft SA, Urbanski SJ, Edwards DR: Compar-
ative analysis of the expression patterns of metalloprotein-
ases and their inhibitors in breast neoplasia, sporadic
colorectal neoplasia, pulmonary carcinomas and malignant
non-Hodgkin's lymphomas in humans.  Br J Cancer 1996,
73:1401-1408.
93. McCawley LJ, Crawford HC, King LEJ, Mudgett J, Matrisian LM: A
protective role for matrix metalloproteinase-3 in squamous
cell carcinoma.  Cancer Res 2004, 64:6965-6972.
94. Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM: Activa-
tion of the Wnt pathway in non small cell lung cancer: evi-
dence of dishevelled overexpression.  Oncogene 2003,
22:7218-7221.
95. Wissmann C, Wild PJ, Kaiser S, Roepcke S, Stoehr R, Woenckhaus M,
Kristiansen G, Hsieh JC, Hofstaedter F, Hartmann A, Knuechel R,
Rosenthal A, C. P: WIF1, a component of the Wnt pathway, is
down-regulated in prostate, breast, lung, and bladder can-
cer.  J Pathol 2003, 201:204-212.
96. Mazieres J, He B, You L, Xu Z, Lee AY, Mikami I, Reguart N, Rosell R,
McCormick F, Jablons DM: Wnt inhibitory factor-1 is silenced by
promoter hypermethylation in human lung cancer.  Cancer
Res 2004, 64:4717-4720.
97. Lee AY, He B, You L, Dadfarmay S, Xu Z, Mazieres J, Mikami I,
McCormick F, Jablons DM: Expression of the secreted frizzled-
related protein gene family is downregulated in human mes-
othelioma.  Oncogene 2004, 23:6672-6676.
98. Di Stefano A, Maestrelli P, Roggeri A, Turato G, Calabro S, Potena A,
Mapp CE, Ciaccia A, Covacev L, Fabbri LM: Upregulation of adhe-
sion molecules in the bronchial mucosa of subjects with
chronic obstructive bronchitis.  Am J Respir Crit Care Med 1994,
149:803-810.
99. Mattoli S, Marini M, Fasoli A: Expression of the potent inflamma-
tory cytokines, GM-CSF, IL6, and IL8, in bronchial epithelial
cells of asthmatic patients.  Chest 1992, 101:27S-29S.
100. Gibbs DF, Shanley TP, Warner RL, Murphy HS, Varani J, Johnson KJ:
Role of matrix metalloproteinases in models of macrophage-
dependent acute lung injury. Evidence for alveolar macro-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Respiratory Research 2006, 7:15 http://respiratory-research.com/content/7/1/15
Page 10 of 10
(page number not for citation purposes)
phage as source of proteinases.  Am J Respir Cell Mol Biol 1999,
20:1145-1154.
101. Warner RL, Beltran L, Younkin EM, Lewis CS, Weiss SJ, Varani J, John-
son KJ: Role of stromelysin 1 and gelatinase B in experimental
acute lung injury.  Am J Respir Cell Mol Biol 2001, 24:537-544.
102. Watari M, Watari H, DiSanto ME, Chacko S, Shi GP, Strauss JF: Pro-
inflammatory cytokines induce expression of matrix-metab-
olizing enzymes in human cervical smooth muscle cells.  Am
J Pathol 1999, 154:1755-1762.
103. Bond M, Baker AH, Newby AC: Nuclear factor kappaB activity
is essential for matrix metalloproteinase-1 and -3 upregula-
tion in rabbit dermal fibroblasts.  Biochem Biophys Res Commun
1999, 264:561-567.
104. Sen M, Reifert J, Lauterbach K, Wolf V, Rubin JS, Corr M, Carson DA:
Regulation of fibronectin and metalloproteinase expression
by Wnt signalling in Rheumatoid Arthritis Synoviocytes.
Arthritis&Rheumatism 2002, 46:2867-2877.
105. Warner RL, Bhagavathula N, Nerusu KC, Lateef H, Younkin E, John-
son KJ, Varani J: Matrix metalloproteinases in acute inflamma-
tion: induction of MMP-3 and MMP-9 in fibroblasts and
epithelial cells following exposure to pro-inflammatory
mediators in vitro.  Exp Mol Pathol 2004, 76:189-195.
106. Kim K, Lu Z, Hay ED: Direct evidence for a role of beta-catenin/
LEF-1 signaling pathway in induction of EMT.  Cell BiolInt 2002,
26:463-476.
107. Swaisgood CM, French EL, Noga C, Simon RH, Ploplis VA: The
development of bleomycin-induced pulmonary fibrosis in
mice deficient for components of the fibrinolytic system.  Am
J Pathol 2000, 157:177-187.
108. Cho SH, Ryu CH, Oh CK: Plasminogen activator inhibitor-1 in
the pathogenesis of asthma.  Exp Biol Med 2004, 229:138-146.
109. Brabletz T, Jung A, Dag S, Hlubek F, Kirchner T: ß-Catenin Regu-
lates the Expression of the Matrix Metalloproteinase-7 in
Human Colorectal Cancer.  Am J Pathol 1999, 155:1033-1038.
110. Bühling F, Röcken C, Brasch F, Hartig R, Yasuda Y, Saftig P, Brömme
D, Welte T: Pivotal Role of Cathepsin K in Lung Fibrosis.  Am
J Pathol 2004, 164:2203-2216.
111. Zuo F, Kaminski N, Eugui E, Allard J, Yakhini Z, Ben-Dor A, Lollini L,
Morris D, Kim Y, DeLustro B, Sheppard D, Pardo A, Selman M, Heller
RA: Gene expression analysis reveals matrilysin as a key reg-
ulator of pulmonary fibrosis in mice and humans.  Proc Natl
Acad Sci USA 2002, 99:6292-6297.
112. Chilosi M, Poletti V, Zamò A, Lestani M, Montagna L, Piccoli P, Pedron
S, Bertaso M, Scarpa A, Murer B, Cancellieri A, Maestro R, Semen-
zato|| G, Doglioni C: Aberrant Wnt/ß-Catenin Pathway Activa-
tion in Idiopathic Pulmonary Fibrosis.  Am J Pathol 2003,
162:1495-1502.
113. Weaver M, Dunn NR, Hogan BLM: Bmp4 and Fgf10 play oppos-
ing roles during lung bud morphogenesis.  Development 2000,
127:2695-2704.
114. Sekiya T, Adachi S, Kohu K, Yamada T, Higuchi O, Furukawa Y, Naka-
mura Y, Nakamura T, Tashiro K, Kuhara S, Ohwada S, Akiyama T:
Identification of BMP and activin membrane-bound inhibitor
(BAMBI), an inhibitor of transforming growth factor-beta
signaling, as a target of the beta-catenin pathway in colorec-
tal tumor cells.  J Biol Chem 2004, 279:6840-6846.
115. Onichtchouk D, Chen YG, Dosch R, Gawantka V, Delius H, Massague
J, Niehrs C: Silencing of TGF-beta signalling by the pseudore-
ceptor BAMBI.  Nature 1999, 401:480-485.
116. Miyazono K, Kusanagi K, Inoue H: Divergence and convergence
of TGF-beta/BMP signaling.  J Cell Physiol 2001, 187:265-276.
117. Lei S, Dubeykovskiy A, Chakladar A, Wojtukiewicz L, Wang TC: The
murine gastrin promoter is synergistically activated by
transforming growth factor-b/Smad and Wnt signaling path-
ways.  J Biol Chem 2004, 279:42492-42502.
118. Hussein SM, Duff EK, Sirard C: Smad4 and -Catenin Co-activa-
tors Functionally Interact with Lymphoid-enhancing Factor
to Regulate Graded Expression of Msx2.  J Biol Chem 2003,
278:48805-48814.
119. Kasai H, Allen JT, Mason RM, Kamimura T, Zhang Z: TGF-b1
induces human alveolar epithelial to mesenchymal cell tran-
sition (EMT).  Respiratory Res 2005, 6:56.